Milnacipran

Generic Name
Milnacipran
Brand Names
Savella
Drug Type
Small Molecule
Chemical Formula
C15H22N2O
CAS Number
92623-85-3
Unique Ingredient Identifier
G56VK1HF36
Background

Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression . Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia , although other regional ...

Indication

Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the management of fibromyalgia in patients that are 18 years old or above .
...

Associated Conditions
Fibromyalgia
Associated Therapies
-

The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients

First Posted Date
2011-05-25
Last Posted Date
2015-09-18
Lead Sponsor
Loma Linda University
Registration Number
NCT01359826
Locations
🇺🇸

Loma Linda University Medical Center, Loma Linda, California, United States

Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism

First Posted Date
2011-04-19
Last Posted Date
2020-02-27
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
10
Registration Number
NCT01337700
Locations
🇺🇸

Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States

Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2011-04-07
Last Posted Date
2013-09-30
Lead Sponsor
Forest Laboratories
Target Recruit Count
57
Registration Number
NCT01331109
Locations
🇺🇸

Forest Investigative Site 042, San Antonio, Texas, United States

🇺🇸

Forest Investigative Site 063, Seattle, Washington, United States

🇺🇸

Forest Investigative Site 017, Louisville, Kentucky, United States

and more 28 locations

Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis

Phase 4
Conditions
Interventions
First Posted Date
2011-04-05
Last Posted Date
2011-08-17
Lead Sponsor
Analgesic Solutions
Target Recruit Count
50
Registration Number
NCT01329406
Locations
🇺🇸

Analgesic Solutions, Natick, Massachusetts, United States

Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2011-04-04
Last Posted Date
2019-05-14
Lead Sponsor
Forest Laboratories
Target Recruit Count
116
Registration Number
NCT01328002
Locations
🇺🇸

Forest Investigative Site 033, Bullhead City, Arizona, United States

🇺🇸

Forest Investigative Site 049, Whitehouse Station, New Jersey, United States

🇺🇸

Forest Investigative Site 046, Greer, South Carolina, United States

and more 44 locations

Preventive Treatment of Episodic and Chronic Migraine

First Posted Date
2011-03-22
Last Posted Date
2011-03-22
Lead Sponsor
California Medical Clinic for Headache
Target Recruit Count
45
Registration Number
NCT01319825
Locations
🇺🇸

California Medical Clinic for Headache, Santa Monica, California, United States

Savella in Treatment for Provoked Vestibulodynia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2011-02-25
Last Posted Date
2018-06-11
Lead Sponsor
University of Tennessee
Target Recruit Count
31
Registration Number
NCT01304589
Locations
🇺🇸

Women's Health Specialists, PLLC, Germantown, Tennessee, United States

Effects of Milnacipran on Widespread Mechanical and Thermal Hyperalgesia of Fibromyalgia Patients

Phase 1
Completed
Conditions
Interventions
First Posted Date
2011-02-11
Last Posted Date
2014-07-31
Lead Sponsor
University of Florida
Target Recruit Count
51
Registration Number
NCT01294059
Locations
🇺🇸

Center for Musculoskeletal Pain Research, Gainesville, Florida, United States

"MILNACIPRAN" in Subjects With Chronic Shoulder Pain

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-02-03
Last Posted Date
2012-08-09
Lead Sponsor
Valera Bussell
Target Recruit Count
40
Registration Number
NCT01289236
Locations
🇺🇸

Delray Research Associates, Delray Beach, Florida, United States

A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain

First Posted Date
2011-02-03
Last Posted Date
2020-09-03
Lead Sponsor
Columbia University
Target Recruit Count
6
Registration Number
NCT01288937
Locations
🇺🇸

Columbia University Medical Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath